Tyra Biosciences’ shares plunged sharply in pre-open trading, losing 31.1% to reach $18.42 after the company disclosed top-line results from its Phase 2 SURF302 study evaluating oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC).
The readout showed an overall response rate (ORR) of 79%, while the best overall complete response (CR) rate at the company’s selected 60 mg once-daily dose was 64%. That CR figure fell below the benchmark many analysts had publicly identified as the minimum acceptable outcome for the program’s success.
The SURF302 trial was intended to provide clinical proof of concept for selective oral FGFR3 inhibition in this patient population. Tyra had identified the 60 mg once-daily regimen as the dose to potentially support a planned registrational adjuvant development strategy.
Market participants reacted to the gap between the reported CR and the pre-set analyst expectations. Analysts at Piper Sandler - who maintained an Overweight rating and a $56 price target on the shares - had modeled the intermediate-risk non-muscle invasive bladder cancer indication as a greater-than-$1 billion opportunity for dabogratinib. Both Piper Sandler and H.C. Wainwright had publicly characterized a 70% three-month complete response rate as the threshold for a successful outcome, meaning the 64% result missed that consensus yardstick.
Investors also noted the safety data. Across the 60 mg and 50 mg cohorts, adverse events were mostly Grade 1-2, with no Grade 4-5 events reported. At the 60 mg dose, the company reported no dose reductions or treatment-related discontinuations. Nevertheless, the efficacy metric shortfall dominated the market response.
The move in the stock was amplified by prior positioning. Shares had climbed about 13% in the week leading up to the announcement, leaving the company exposed after market participants had priced in a strong outcome.
Macro and market context
The broader market offered limited support during the pre-market session. Major U.S. indices - the S&P 500, the Dow Jones Industrial Average and the Nasdaq - were modestly negative, a backdrop that added to downward pressure on speculative biotech names.
Compounding investor caution was a stronger-than-expected August nonfarm payrolls report, which showed employment rising by 162,000 - nearly triple estimates - while the unemployment rate remained at 4.1%. That print has raised questions about the Federal Reserve’s upcoming policy direction, introducing additional macro uncertainty into an already risk-off session for higher-volatility sectors.
Why the stock moved
The selloff appears driven by three linked dynamics: a CR rate that missed a well-publicized analyst benchmark; shares that had been bid up ahead of the readout; and a cautious macro environment that reduces investors’ willingness to tolerate binary clinical-risk outcomes. Although management designated 60 mg once-daily as the dose to support registrational adjuvant development and indicated plans to explore a 70 mg cohort, the immediate market reaction refl ects heightened uncertainty over the drug’s regulatory and commercial trajectory following the below-threshold efficacy result.
For now, investors are repricing Tyra’s equity to reflect that uncertainty while weighing the favorable safety profile against the efficacy shortfall.
Summary takeaway
Tyra Biosciences delivered a strong overall response rate in SURF302 but did not meet the 70% CR threshold flagged by several analysts at the selected 60 mg dose. The combination of elevated expectations, a recent run-up in the stock, and a risk-off market environment produced a sharp pre-market decline as the market recalibrated the company’s near-term regulatory and commercial prospects.